1808 related articles for article (PubMed ID: 19638963)
21. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
22. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.
Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ
J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707
[TBL] [Abstract][Full Text] [Related]
23. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
24. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
25. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
26. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
27. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus.
Kerkhof M; Steyerberg EW; Kusters JG; van Dekken H; van Vuuren AJ; Kuipers EJ; Siersema PD
Cancer Biomark; 2008; 4(1):1-10. PubMed ID: 18334729
[TBL] [Abstract][Full Text] [Related]
28. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
29. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
[TBL] [Abstract][Full Text] [Related]
30. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
Cronin J; McAdam E; Danikas A; Tselepis C; Griffiths P; Baxter J; Thomas L; Manson J; Jenkins G
Am J Gastroenterol; 2011 Jan; 106(1):46-56. PubMed ID: 21157443
[TBL] [Abstract][Full Text] [Related]
32. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
[TBL] [Abstract][Full Text] [Related]
33. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
34. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
[TBL] [Abstract][Full Text] [Related]
35. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
36. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
37. Is there an advantage to be gained from adding digital image cytometry of brush cytology to a standard biopsy protocol in patients with Barrett's esophagus?
Borovicka J; Schönegg R; Hell M; Kradolfer D; Bauerfeind P; Dorta G; Netzer P; Binek J; Meyenberger C; Fischer JE; Spieler P
Endoscopy; 2009 May; 41(5):409-14. PubMed ID: 19418394
[TBL] [Abstract][Full Text] [Related]
38. Clinical use of p53 in Barrett's esophagus.
Keswani RN; Noffsinger A; Waxman I; Bissonnette M
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
[TBL] [Abstract][Full Text] [Related]
39. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
40. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
